Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
Voclosporin Lupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Market Phase not started
Voclosporin Nephrotic Syndrome
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Voclosporin Opthalmic Solution Dry Eye Syndrome
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is working to potentially deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

About Voclosporin

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,400 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). MMF is not approved for LN by the U.S. Food & Drug Administration (FDA). Voclosporin has been granted “fast track status” by the FDA.